Insulin Aspart Sanofi

Insulin Aspart, the active ingredient in Insulin Aspart Sanofi, is a rapid‑acting insulin analog presented as a solution for subcutaneous use. It is used to control blood glucose levels in patients with diabetes mellitus, including both type 1 and type 2 disease, by providing a fast‑acting insulin replacement after meals.

GNH USA supplies Insulin Aspart Sanofi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Insulin Aspart is a rapid‑acting insulin analog indicated for diabetes mellitus management.

- Type 1 diabetes mellitus: improves post‑prandial glucose control and reduces hyperglycaemia. - Type 2 diabetes mellitus: helps achieve glycaemic targets in patients requiring insulin therapy. - Intensive insulin therapy: enables flexible dosing around meals for tighter glucose regulation.

Insulin Aspart may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hypoglycaemia: low blood glucose levels, especially if meals are missed. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: modest increase due to improved glucose utilisation. - Lipodystrophy: localized changes in subcutaneous fat. - Nausea: occasional gastrointestinal discomfort. - Headache: mild to moderate intensity.

Serious or Rare Side Effects: - Severe hypoglycaemia: can lead to loss of consciousness or seizures. - Allergic reaction or anaphylaxis: hives, swelling, or breathing difficulty. - Insulin antibodies: may alter drug effectiveness. - Hypokalemia: low potassium levels. - Edema: fluid retention, especially in lower extremities. - Acute pancreatitis: rare but serious pancreatic inflammation.

When using Insulin Aspart, several safety considerations should be observed.

- Dose adjustment: tailor the dose to carbohydrate intake and current blood glucose levels. - Renal impairment: monitor closely as insulin clearance may be reduced. - Hepatic impairment: use with caution; hypoglycaemia risk may increase. - Pregnancy: limited data; consult a healthcare professional before use. - Hypoglycaemia risk: educate patients on recognising and treating low blood glucose. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insulin Aspart can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Sulfonylureas: combined use may cause profound hypoglycaemia. - Beta‑blockers: may mask typical hypoglycaemia symptoms. - Systemic corticosteroids: can increase insulin resistance, requiring dose adjustments.

Moderate Interactions (Monitor Closely): - ACE inhibitors: may potentiate hypoglycaemic episodes. - Thiazide diuretics: can affect glucose metabolism and insulin sensitivity.